Evidence map›Paper›PMID 21785422›Full record

ArticleNature cell biology2011

esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function.

Lena Ho, Erik L Miller, Jehnna L Ronan, Wen Qi Ho, Raja Jothi, Gerald R Crabtree

Open access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 1 synthesis or guideline pooled it, 268 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lena HoProgram in Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Erik L Miller
Jehnna L Ronan
Wen Qi Ho
Raja Jothi
Gerald R Crabtree
Stanford University · USHoward Hughes Medical Institute · USNational Institutes of Health · US

Funding

Gene regulatory elements, networks, and mechanismsZIAES102625 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JOTHI, RAJA · 2009 to 2025
$27.4M
Signaling by Calcineurin and NFAT in Axonal OutgrowthR01NS046789 · NINDS · STANFORD UNIVERSITY · PI CRABTREE, GERALD R. · 2003 to 2012
$3.4M
Signaling in T Lymphocyte DevelopmentR01AI060037 · NIAID · STANFORD UNIVERSITY · PI CRABTREE, GERALD R. · 2004 to 2010
$2.4M
NFAT Signaling and Down SyndromeR01HD055391 · NICHD · STANFORD UNIVERSITY · PI CRABTREE, GERALD R. · 2008 to 2012
$1.4M
Howard Hughes Medical InstituteIntramural NIH HHS ZIA ES102625NIAID NIH HHS R01 AI060037NIAID NIH HHS R01AI60037NICHD NIH HHS R01 HD055391NICHD NIH HHS R01HD55391NINDS NIH HHS R01 NS046789NINDS NIH HHS R01NS46789
6 · The paper itself

Abstract

Signalling by the cytokine LIF and its downstream transcription factor, STAT3, prevents differentiation of pluripotent embryonic stem cells (ESCs). This contrasts with most cell types where STAT3 signalling induces differentiation. We find that STAT3 binding across the pluripotent genome is dependent on Brg1, the ATPase subunit of a specialized chromatin remodelling complex (esBAF) found in ESCs. Brg1 is required to establish chromatin accessibility at STAT3 binding targets, preparing these sites to respond to LIF signalling. Brg1 deletion leads to rapid polycomb (PcG) binding and H3K27me3-mediated silencing of many Brg1-activated targets genome wide, including the target genes of the LIF signalling pathway. Hence, one crucial role of Brg1 in ESCs involves its ability to potentiate LIF signalling by opposing PcG. Contrary to expectations, Brg1 also facilitates PcG function at classical PcG targets, including all four Hox loci, reinforcing their repression in ESCs. Therefore, esBAF does not simply antagonize PcG. Rather, the two chromatin regulators act both antagonistically and synergistically with the common goal of supporting pluripotency.

Indexed as

AnimalsChromatin Assembly and DisassemblyDNA HelicasesEmbryonic Stem CellsFemaleGene Expression RegulationGenes, HomeoboxHistonesLeukemia Inhibitory FactorMaleMiceMice, KnockoutModels, BiologicalNuclear ProteinsPluripotent Stem CellsPolycomb-Group ProteinsDNA HelicasesHistonesLeukemia Inhibitory FactorLif protein, mouseNuclear ProteinsPolycomb-Group ProteinsRepressor ProteinsSmarca4 protein, mouseStat3 protein, mouseSTAT3 Transcription FactorTranscription Factors

Identifiers

PMID21785422
PMCPMC3155811
OpenAlexW1981359686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.